TWST241220C55000
- 1.45
- +0.15+11.54%
Twist Bioscience Newsroom
Twist Bioscience Analyst Ratings
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $58
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $52
Twist Bioscience Price Target Raised to $54.00/Share From $50.00 by Scotiabank
Scotiabank Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $54
A Quick Look at Today's Ratings for Twist Bioscience(TWST.US), With a Forecast Between $35 to $58
Twist Bioscience Analyst Ratings
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $48
Twist Bioscience Is Maintained at Market Perform by Leerink Partners
Twist Bioscience Analyst Ratings
Leerink Partners Maintains Twist Bioscience(TWST.US) With Hold Rating, Raises Target Price to $48
Positive Outlook and Strong Pricing Strategy Justify Buy Rating for Twist Bioscience
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $55
Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)
Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $46
Twist Bioscience Analyst Ratings
Evercore Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $56
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Scotiabank Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $50